You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202331 - 202340 of 207728 results
  1. Association Analysis Software for Mining Clinical Next-Gen Sequencing Data

    SBC: VALA SCIENCES, INC.            Topic: NIEHS

    Congenital cardiac defects (CCDs) are among the most common birth defects and fetal cardiac defects likely contribute to miscarriages, which terminate up to 25% of all pregnancies. Environmental factors may influence up to 80% of all CCDs, but little is known about how chemicals from the environment may affect formation of the heart. We propose to develop a cardiopoiesis (formation of the heart) a ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Assay Development for Measuring Chemical Effects on the Epigenome in Stem Cells

    SBC: Xcell Science Incorporated            Topic: NIEHS

    7. Project Summary The recent advances in pluripotent stem cell (PSC) technology enable researchers to establish human tissue derived cellular platforms for toxicity testing that are capable of providing information on mechanism of action, while facilitating the incorporation of broad genetic diversity and clinically validated disease conditions. We and other investigators have shown that it is po ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Endothelial Progenitor Cells for Assessing Toxicological Response Variability in

    SBC: INTEGRATED LABORATORY SYSTEMS, LLC            Topic: NIEHS

    PROJECT SUMARY/ABSTRACT This proposed project is in response to the need for more extensive toxicological evaluation of environmental chemicals and for predictive models to assess associated risks of chemical exposure to humans. There is also need for innovative methods for evaluating the effects of chemicals on pluripotent stem cells and the differentiation process. A novel chromatin structure be ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Stem Cell Panels for Genetic Analysis of Variable Toxicant Effects on Neuronal Ce

    SBC: BRITEBIO, INC.            Topic: NIEHS

    Currently, toxicological risk assessment lacks direct estimation of the magnitude and variability of human responses to environmental toxicants. Specifically, there is very little data on the effects of low dose toxicants on human developmental processes,including cellular differentiation. That is because the current basis of toxicological assessment, animals and immortalized cell lines, cannot ad ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Metabolic assay utilizing neurodevelopmental cells derived from human pluripotent

    SBC: NEWOMICS INC.            Topic: NIEHS

    Project Summary/Abstract There is a paradigm shift in testing and modeling of chemical toxicity. Current toxicology calls for human-cell- based (vs. animal-based), evidence-based, and Omics-based assays. Mesenchymal stem cells (MSC) play important roles inthe maintenance and repair of various tissues, including bone, cartilage, and muscle. MSCs are also found in circulating blood and participate i ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Assays for Screening the Effects of Chemical Toxicants on Cell Differentiat

    SBC: ARUNA BIO, INC.            Topic: NIEHS

    SUMMARY The overarching objective of this Phase I project is to determine the feasibility of developing both focused and broad toxicity metabolomic assays for three neural development associated windows of susceptibility (WOS) for human development. Epidemiological and laboratory studies have identified numerous chemicals suspected to be developmental neurotoxicants. These range from heavy metals ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Stem cell toxicology assays for cardiac differentiation

    SBC: PREDICTIVE BIOLOGY            Topic: NIEHS

    We propose to develop a high throughput in vitro assay to identify genetic factors affecting toxicant impact on neuronal differentiation. This project uses a novel genetic mapping resource developed at Predictive Biology, the Diversity Outbred (DO) Mouse ES Cell Panel. Using robust ES cell engineering methods, we will incorporate neuronal differentiation reporters into DO ES lines. Neuronal Stem C ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Reagents and Methods for Rapid and High Throughput Detection of Aflatoxin C

    SBC: AGRI-ANALYSIS, LLC            Topic: NIEHS

    DESCRIPTION (provided by applicant): This SBIR grant application is in response to PA-11-335, from Lab to Marketplace: Tools for Biomedical and Behavioral Research. The intent of PA-11-335 is to help move useful technologies from non-commercial laboratories into the commercial marketplace by inviting SBIR grant applications from small businesses for further development of such technologies that a ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Developing A Novel Therapy for Diabetic Retinopathy

    SBC: Charlesson, LLC            Topic: NEI

    DESCRIPTION (provided by applicant): Diabetic retinopathy (DR) is a common complication of diabetes and a leading cause of vision loss in the United States. Unfortunately, there is no FDA-approved pharmacotherapy for DR. Current treatments in clinical practice and trails, such as laser photocoagulation, corticosteroids and anti-vascular endothelial growth factor (VEGF) agents, are effective in som ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Portable hand-held non-mydriatic retinal camera

    SBC: VisionQuest Biomedical Inc            Topic: NEI

    DESCRIPTION (provided by applicant): According to the National Institutes of Health, there are more than 80 million people in the US who suffer from a potentially sight-threatening disease. Doctors see seven to eight million new cases of eye disease annually. More than two million Americans age 50 and older have advanced AMD, the stage that can lead to severe vision impairment and 10 million have ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government